Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
M. Valentini, F. Bortoluzzi, C. Cernigoi, G. Toffoli, E. Bertolissi, R. Cannizzaro, M. Sozzi & M. Fornasarig. (1993) Effect of Short- and Long-Term Treatment with Omeprazole on Cell Cycle Distribution in the Gastric Mucosa: Results of a Flow Cytometric Study. Scandinavian Journal of Gastroenterology 28:7, pages 617-621.
Read now
Read now
J. Fryklund, A. K. Falknäs & H. F. Helander. (1992) Omeprazole Does Not Cause Unscheduled DNA Synthesis in Rabbit Parietal Cells in Vitro. Scandinavian Journal of Gastroenterology 27:6, pages 521-528.
Read now
Read now
Tiziana D'Adda, Cinzia Azzoni, Angelo Franzé & Cesare Bordi. (1991) Malignant Enterochromaffinlike Cell Carcinoid of the Gastric Stump: An Ultrastructural Study. Ultrastructural Pathology 15:3, pages 257-265.
Read now
Read now
S. A. M. Selway. (1990) Potential Hazards of Long-Term Acid Suppression. Scandinavian Journal of Gastroenterology 25:sup178, pages 85-92.
Read now
Read now
J. B. M. J. Jansen & C. B. H. W. Lamers. (1990) High Doses of Ranitidine in Patients with Reflux Oesophagitis. Scandinavian Journal of Gastroenterology 25:sup178, pages 42-46.
Read now
Read now
K. G. Wormsley. (1988) Risks of Therapeutic Achlorhydria. Scandinavian Journal of Gastroenterology 23:sup153, pages 35-51.
Read now
Read now
J. J. Misiewicz. (1988) Effects of Pirenzepine, Prostaglandin Analogues, and Omeprazole on Gastric Function. Scandinavian Journal of Gastroenterology 23:sup153, pages 2-14.
Read now
Read now
M. Simonsson, S. Eriksson, R. Håkanson, T. Lind, H. Lönroth, L. Lundell, D. T. O'connor & F. Sundler. (1988) Endocrine Cells in the Human Oxyntic Mucosa: A Histochemical Study. Scandinavian Journal of Gastroenterology 23:9, pages 1089-1099.
Read now
Read now
C. T. Eason, A. Pattison, D. D. Howells, A. J. Spencer & F. W. Bonner. (1988) Assessment of Gastric Antisecretory Effects of Phenoxyisobutyrate Derivatives in the Rat and the Mouse. Scandinavian Journal of Gastroenterology 23:9, pages 1063-1071.
Read now
Read now
J. H. Harleman, G. R. Betton, C. Dormer & M. McCrossan. (1987) Gastric Neuroendocrine Cell Hyperplasia after Treatment with the Long-Acting, Potent H2-Receptor Antagonist SK&F 93479. Scandinavian Journal of Gastroenterology 22:5, pages 595-600.
Read now
Read now
E. Kittang, E. Aadland, H. Schjønsby & K. Røhss. (1987) The Effect of Omeprazole on Gastric Acidity and the Absorption of Liver Cobalamins. Scandinavian Journal of Gastroenterology 22:2, pages 156-160.
Read now
Read now
A. Garner. (1986) Future Opportunities for Drug Therapy in Peptic Ulcer Disease. Scandinavian Journal of Gastroenterology 21:sup125, pages 203-211.
Read now
Read now
H. R. Koelz. (1986) Protective Drugs in the Treatment of Gastroduodenal Ulcer Disease. Scandinavian Journal of Gastroenterology 21:sup125, pages 156-164.
Read now
Read now
M. J. S. Langman. (1986) Does Treatment Present Material Risks?. Scandinavian Journal of Gastroenterology 21:sup125, pages 61-70.
Read now
Read now
Frank Sundler, Enar Carlsson, Rolf Hakånson, Håkan Larsson & Hillevi Mattsson. (1986) Inhibition of Gastric Acid Secretion by Omeprazole and Ranitidine. Effects on Plasma Gastrin and Gastric Histamine, Histidine Decarboxylase Activity and ECL Cell Density in Normal and Antrectomized Rats. Scandinavian Journal of Gastroenterology 21:sup118, pages 39-45.
Read now
Read now
Articles from other publishers (74)
Lingaku Lee, Irene Ramos-Alvarez, Tetsuhide Ito & Robert T. Jensen. (2019) Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome. International Journal of Molecular Sciences 20:20, pages 5128.
Crossref
Crossref
Nathan Boersen, Thomas Lee & Ho-Wah Hui. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development
69
86
.
Andreas W. Herling. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
199
255
.
Wolfgang Kromer, Stefan Postius, Uwe Krüger & C. Robin Ganellin. 2000. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Peter Greaves. 2012. Histopathology of Preclinical Toxicity Studies. Histopathology of Preclinical Toxicity Studies
99
155
.
M Kidd, Z-L Siddique, I. Drozdov, B.I. Gustafsson, R.L. Camp, J.W. Black, M. Boyce & I.M. Modlin. (2010) The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regulatory Peptides 162:1-3, pages 52-60.
Crossref
Crossref
Benjamin J. Vesper, Kenneth W. Altman, Kim M. Elseth, G. Kenneth HainesIIIIII, Sylvia I. Pavlova, Lin Tao, Gabor Tarjan & James A. Radosevich. (2008) Gastroesophageal Reflux Disease (GERD): Is There More to the Story?. ChemMedChem 3:4, pages 552-559.
Crossref
Crossref
Yu Mao, Xiaodong Zhang, Li Li, Bojun Yuan & Guocai Lu. (2008) Subchronic toxicity and toxicokinetics of LZB, a new proton pump inhibitor, after 13-week repeated oral administration in dogs. Regulatory Toxicology and Pharmacology 50:1, pages 75-86.
Crossref
Crossref
Peter Greaves. 2007. Histopathology of Preclinical Toxicity Studies. Histopathology of Preclinical Toxicity Studies
99
159
.
Jeffrey N. Hemenway. 2007. Prodrugs. Prodrugs
1313
1321
.
. (2004) Effects of Ethylacetate Fraction of Plantain (Plantago asiatica L.) on Experimentally-Induced Gastric Mucosal Damage and Gastric Ulcers in Rats. Journal of the Korean Society of Food Science and Nutrition 33:4, pages 659-667.
Crossref
Crossref
Blanca Sinués, Ana Fanlo, Marĺa Luisa Bernal, Marta Val & Esteban Mayayo. (2016) Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans. Human & Experimental Toxicology 23:3, pages 107-113.
Crossref
Crossref
Kazuo OkimotoIzumi MatsumotoKoji KurokiKohji Tanaka. (2003) Spontaneous Gastric Carcinoid Tumor in a Male B6C3F1 Mouse. Journal of Toxicologic Pathology 16:3, pages 175-178.
Crossref
Crossref
Robert T. Jensen. (2003) Involvement of Cholecystokinin/Gastrin‐Related Peptides and their Receptors in Clinical Gastrointestinal Disorders. Pharmacology & Toxicology 91:6, pages 333-350.
Crossref
Crossref
Armen H. TashjianJR.JR. & Bruce A. Chabner. (2009) Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women. Journal of Bone and Mineral Research 17:7, pages 1151-1161.
Crossref
Crossref
S. Bashir, F. Gibril, J. V. Ojeaburu, B. Asgharian, L. K. Entsuah, G. Ferraro, P. Crafa, C. Bordi & R. T. Jensen. (2002) Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Alimentary Pharmacology & Therapeutics 16:7, pages 1367-1382.
Crossref
Crossref
Celia Alemán, Idania Rodeiro, Miriam Noa, Roberto Menéndez, Rafael Gaméz, Caridad Hernandez & Rosa Más. (2001) One‐year dog toxicity study of D‐002, a mixture of aliphatic alcohols. Journal of Applied Toxicology 21:3, pages 179-184.
Crossref
Crossref
Enrique RozengurtJohn H Walsh. (2001) Gastrin, CCK, Signaling, and Cancer. Annual Review of Physiology 63:1, pages 49-76.
Crossref
Crossref
K. H. Moore, P. Barry, J. Burn & G. Falk. (2001) Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. Diseases of the Esophagus 14:1, pages 17-22.
Crossref
Crossref
R Dawson & J McK Manson. (2000) Omeprazole in oesophageal reflux disease. The Lancet 356:9243, pages 1770-1771.
Crossref
Crossref
Wolfgang Kromer, Stefan Postius & Uwe Krüger. 2000. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Laine, Ahnen, Mcclain, Solcia & Walsh. (2001) Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 14:6, pages 651-668.
Crossref
Crossref
Waldum & Brenna. (2000) Personal review: is profound acid inhibition safe?. Alimentary Pharmacology & Therapeutics 14:1, pages 15-22.
Crossref
Crossref
Peter Greaves. 2000. Histopathology of Preclinical Toxicity Studies. Histopathology of Preclinical Toxicity Studies
87
156
.
Tetsuya SEKI, Nobuyuki OHBA, Hitoshi FUNATOMI, Kazuya UTAHASHI, Keiichiro YONEYAMA & Keiji MITAMURA. (1999) A Case of Omerpazole-induced Gynecomastia Not Ascribed to Hormonal Abnormalities. The Showa University Journal of Medical Sciences 11:1, pages 45-52.
Crossref
Crossref
TAKEUCHI, HIRATA, YAMAMOTO, KUNIKATA, ISHIKAWA & ISHIHARA. (2001)
Effects of S‐0509, a novel CCK
B
/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats
. Alimentary Pharmacology & Therapeutics 13:1, pages 87-96.
Crossref
Crossref
Enar Carlsson & Niilo Havu. 1999. Proton Pump Inhibitors. Proton Pump Inhibitors
79
89
.
Robert T. Jensen. 1999. Proton Pump Inhibitors. Proton Pump Inhibitors
205
221
.
B. Stoschus, G. Hamscher, S. Ikonomou, G. Partoulas, C. Eberle, T. Sauerbruch & G.E. Feurle. (2009) Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gastrin and somatostatin, and of pepsinogen. The Journal of Peptide Research 52:1, pages 27-33.
Crossref
Crossref
Stewart, Termanini, Sutliff, Serrano, Yu, Gibril & Jensen. (2001) Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy. Alimentary Pharmacology & Therapeutics 12:1, pages 83-98.
Crossref
Crossref
Shinsuke Takeno, Tsutomu Daa, Hiroshi Shimoda, Shigeo Yokoyama, Lwao Nakayama & Yuzo Uchida. (2008)
Effects of gastrin on the histamine‐secretory and proliferative activity of cultured carcinoid cells derived from the stomach of the rodent
Mastomys natalensis
. Pathology International 47:2-3, pages 95-102.
Crossref
Crossref
Rod Dimaline. (2007) Molecular control of peptide hormone and receptor expression. Proceedings of the Nutrition Society 55:1B, pages 265-277.
Crossref
Crossref
Francesco Di Mario, Giuseppe Battaglia, Michele De Boni, Emanuela De Bona, Gioacchino Leandro, Giorgio Chiozzini, Michele Pasini, Giovanni Andrea Grasso, Marina Ferrana, Alfredo Saggioro & Marcello Pasquino. (1996) Omeprazole in the maintenance treatment of duodenal ulcer: results after 6 months of 20 mg daily, 20 mg every other day, or 40 mg on weekends. Current Therapeutic Research 57:1, pages 33-41.
Crossref
Crossref
A. Hurwitz, M. I. Sztern, G. A. Looney, D. M. Pinson, K. D. Bauer & B. F. Kimler. (2008) Effects of omeprazole on cell kinetics of carcinogen‐induced colon tumours in rats. Cell Proliferation 28:10, pages 525-531.
Crossref
Crossref
S. BANERJEE, J. E. S. ARDILL, A. D. BEATTIE & K. E. L. McCOLL. (2007) Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Alimentary Pharmacology & Therapeutics 9:5, pages 507-512.
Crossref
Crossref
A. Romero, F. Gömez, F. Villamayor, A. Sacristán & J‐A. Ortíz. (2008) Effect of ebrotidine on the density of antral G‐cells in the gastric mucosa in the rat. Cell Proliferation 28:7, pages 393-401.
Crossref
Crossref
J. B. Meko, M.D & J. A. Norton, M.D. (1995) MANAGEMENT OF PATIENTS WITH ZOLLINGER-ELLISON SYNDROME. Annual Review of Medicine 46:1, pages 395-411.
Crossref
Crossref
G. BIANCHI PORRO, R. CORINALDESI, M. LAZZARONI, L. BARBARA, L. CAPURSO, P. PAOLUZI, A. MANGIAMELI, F. SABBATINI, M. FRANCESCHI & E. BOLLING. (2007) Long term treatment with omeprazole 20 mg three days a week or 10 mg daily in the prevention of duodenal ulcer relapse. Alimentary Pharmacology & Therapeutics 8:5, pages 541-548.
Crossref
Crossref
James S. MacDonald, George R. Lankas & Richard E. Morrissey. (2016) Toxicokinetic and Mechanistic Considerations in the Interpretation of the Rodent Bioassay. Toxicologic Pathology 22:2, pages 124-140.
Crossref
Crossref
E. S. Harpur & F. W. Bonner. 1994. Use of Mechanistic Information in Risk Assessment. Use of Mechanistic Information in Risk Assessment
176
182
.
I D Penman, E el-Omar, J R McGregor, K J Hillan, P J O'Dwyer & K E McColl. (1993) Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats.. Gut 34:11, pages 1559-1565.
Crossref
Crossref
J. Gregory McKinnon. (2006) Palliative treatment of neuroendocrine tumors. Seminars in Surgical Oncology 9:5, pages 453-458.
Crossref
Crossref
Firouzan Massoomi, John Savage & Christopher J. Destache. (2012) Omeprazole: A Comprehensive Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 13:1, pages 46-59.
Crossref
Crossref
F. Halter & A. Schmassmann. 1993. Der Magen. Der Magen
65
75
.
F. Halter & A. Schmassmann. 1993. The Stomach. The Stomach
58
67
.
F. von Bruchhausen, S. Ebel, E. Hackenthal, G. Dannhardt, A. W. Frahm, U. Holzgrabe, K. Keller, E. Nürnberg, H. Rimpler, G. Schneider, P. Surmann, H. U. Wolf & G. Wurm. 1993. Hagers Handbuch der Pharmazeutischen Praxis. Hagers Handbuch der Pharmazeutischen Praxis
1221
1293
.
P. CARUANA, C. AZZONI, A. BERTELÉ, B. ANNIBALE, A. FRANZÉ, G. DELLE FAVE & C. BORDI. (2007) Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger–Ellison syndrome during omeprazole treatment. Histopathology 21:4, pages 359-363.
Crossref
Crossref
E. BRENNA, H. L. WALDUM, A. K. SANDVIK, B. SCHULZE SØGNEN & A. KRISTENSEN. (2007)
Effects on the rat oxyntic mucosa of the histamine
2
‐antagonist loxtidine and the H
+
, K
+
‐ATPase inhibitor omepvazole
. Alimentary Pharmacology & Therapeutics 6:3, pages 335-349.
Crossref
Crossref
Thomas A. Lampkin, Daniele Ouellet, Lawrence J. Hak & George E. Dukes. (2016) Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders. DICP 24:4, pages 393-402.
Crossref
Crossref
H. KOOP, M. KLEIN & R. ARNOLD. (2007) Serum gastrin levels during long‐term omeprazole treatment. Alimentary Pharmacology & Therapeutics 4:2, pages 131-138.
Crossref
Crossref
R. HÅKANSON & F. SUNDLER. (2008) Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis. European Journal of Clinical Investigation 20:1, pages 65-71.
Crossref
Crossref
Per Lindberg, Arne Brändström, Björn Wallmark, Hillevi Mattsson, Leif Rikner & Kurt‐Jürgen Hoffmann. (2006) Omeprazole: The first proton pump inhibitor. Medicinal Research Reviews 10:1, pages 1-54.
Crossref
Crossref
Kenneth G. Wormsley. (1989) Therapeutic achlorhydria and risk of gastric cancer. Gastroenterologia Japonica 24:5, pages 585-596.
Crossref
Crossref
N.W. Spurling, S.A.M. Selway & D. Poynter. (2016) An Evaluation of the Safety of Ranitidine During Seven Years Daily Oral Administration to Beagle Dogs. Human Toxicology 8:1, pages 23-32.
Crossref
Crossref
Andrew J. Spencer, Thomas A. Barbolt, Douglas C. Henry, Charles T. Eason, Richard J. Sauerschell & Frank W. Bonner. (2016) Gastric Morphological Changes Including Carcinoid Tumors in Animals Treated with a Potent Hypolipidemic Agent, Ciprofibrate. Toxicologic Pathology 17:1_part_1, pages 7-15.
Crossref
Crossref
C. GESPACH, D. FAGOt & S. EMAMI. (2008)
Pharmacological control of the human gastric histamine H2 receptor by famotidine: comparison with H
1
, H
2
and H
3
receptor agonists and antagonists
. European Journal of Clinical Investigation 19:1, pages 1-10.
Crossref
Crossref
Haile T. Debas & Michael W. Mulholland. (1989) Drug therapy in peptic ulcer disease. Current Problems in Surgery 26:1, pages 9-54.
Crossref
Crossref
G. CADIOT, THERESE LEHY & S. BONFILS. (2008) Action of somatostatin analogue (SMS 201–995) on the growth‐promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour. European Journal of Clinical Investigation 18:4, pages 360-368.
Crossref
Crossref
S. LANZON‐MILLER, M. C. ALLISON, R. E. POUNDER, S. BALL, M. R. HAMILTON & N. A. F. CHRONOS. (2007) Enprostil inhibits post‐prandial gastrin release: a dose—response study. Alimentary Pharmacology & Therapeutics 2:4, pages 317-323.
Crossref
Crossref
J. M. POLAK & S. R. BLOOM. (2007) Review: the enterochromaffin‐like cell, intragastric acidity and the trophic effect of plasma gastrin. Alimentary Pharmacology & Therapeutics 2:4, pages 291-296.
Crossref
Crossref
C.T. Eason, A.J. Spencer, A. Pattison, D.D. Howells, D.C. Henry & F.W. Bonner. (2016) The Toxicological Consequences of the Gastric Antisecretory Activity of Ciprofibrate in the Rat. Human Toxicology 7:2, pages 222-223.
Crossref
Crossref
Graham R. Betton, Charles S. Dormer, Terry Wells, Pauline Pert, Carolyn A. Price & Peter Buckley. (2016)
Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H
2
-Antagonists SK&F 93479 and Oxmetidine and Omeprazole
. Toxicologic Pathology 16:2, pages 288-298.
Crossref
Crossref
Robert S. Hirth, Lorraine D. Evans, Robert A. Buroker & Frederick B. Oleson. (2016)
Gastric Enterochromaffin-Like Cell Hyperplasia and Neoplasia in the Rat: An Indirect Effect of the Histamine H
2
-Receptor Antagonist, BL-6341
. Toxicologic Pathology 16:2, pages 273-287.
Crossref
Crossref
Håkan Larsson, Rolf Håkanson, Hillevi Mattsson, Birgitta Ryberg, Frank Sundler & Enar Carlsson. (2016) Omeprazole: Its Influence on Gastric Acid Secretion, Gastrin and ECL Cells. Toxicologic Pathology 16:2, pages 267-272.
Crossref
Crossref
Cesare Bordi, Tiziana D’Adda, Francesco Paolo Pilato & Corrado Ferrari. 1988. Progress in Surgical Pathology. Progress in Surgical Pathology
177
195
.
C. K. Atterwill & C. G. Brown. 1988. The Target Organ and the Toxic Process. The Target Organ and the Toxic Process
71
79
.
. (1987) Communications. British Journal of Pharmacology 91:S1, pages 293P-510P.
Crossref
Crossref
G. N. J. TYTGAT, C. B. H. W. LAMERS, W. HAMEETEMAN, J. M. B. J. JANSEN & J. A. WILSON. (2007) Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Alimentary Pharmacology & Therapeutics 1:1, pages 31-38.
Crossref
Crossref
C. Gopinath, D. E. Prentice & D. J. LewisC. Gopinath, D. E. Prentice & D. J. Lewis. 1987. Atlas of Experimental Toxicological Pathology. Atlas of Experimental Toxicological Pathology
61
76
.
G. H. Hottendorf. 1987. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques
257
272
.
P. J. PRICHARD, N. D. YEOMANS, A. SHULKES, D. B. JONES, P. J. BUCKLE, R. A. SMALLWOOD & W. J. LOUIS. (2008) The effect of omeprazole on 24 h intragastric pH and fasting plasma gastrin during low dosage (10 mg) in the morning or the evening. Journal of Gastroenterology and Hepatology 1:4, pages 289-295.
Crossref
Crossref
S H Anderson & T J Charles. (1985) Parenteral nutrition.. BMJ 291:6510, pages 1723-1724.
Crossref
Crossref
E Ernst, A Matrai & M Baumann. (1985) Fibrinogen: a possible link between social class and coronary heart disease.. BMJ 291:6510, pages 1723-1723.
Crossref
Crossref
F. Wells. (1985) Misleading guidelines on oxygen treatment in asthma. BMJ 291:6510, pages 1722-1723.
Crossref
Crossref